Document is current
Any future updates will be listed below
-
Authors
Hennermann, Julia B.
Raebel, Eva M. https://orcid.org/0000-0002-6242-9174
Donà, Francesca
Jacquemont, Marie-Line
Cefalo, Graziella
Ballabeni, Andrea
Malm, Dag
-
Funding
Funding for this research was provided by:
Chiesi Farmaceutici
- License Information
-
More Information
Article History
Received: 21 February 2022
Accepted: 30 June 2022
First Online: 23 July 2022
Declarations
:
: Ethical approval was not required. Consent was obtained from participants. RDRP conduct their research in accordance with the British Healthcare Business Intelligence Association's Legal and Ethical Guidelines.
: Not applicable.
: JBH has received consulting fees and/or travelling expenses by Amicus, Chiesi Farmaceutici S.p.A and Takeda; EMR is employed by the Rare Disease Research Partners, which supplies various professional services to Chiesi Farmaceutici S.p.A.; FD and AB are employees of Chiesi Farmaceutici S.p.A; GC has received advisory board fees from Chiesi Farmaceutici S.p.A.; M-LJ and DM have no competing interests to declare.
